⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727484 | 1.00 | — | — | |
| SCHEMBL2985550 | 1.00 | — | — | |
| SCHEMBL17162480 | 1.00 | — | — | |
| SCHEMBL2909263 | 1.00 | — | — | |
| SCHEMBL2913695 | 1.00 | — | — | |
| SCHEMBL17162469 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2918760 | 0.99 | — | — | |
| SCHEMBL3043623 | 0.90 | — | — | |
| SCHEMBL3792793 | 0.90 | — | — | |
| SCHEMBL3038336 | 0.87 | PER2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642339-B2 | Methods of treating symptoms of gastroparesis using velusetrag | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | claimed |
| US-20190030022-A1 | METHODS OF TREATING SYMPTOMS OF GASTROPARESIS USING VELUSETRAG | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-31 | — | — | US | claimed |
| EP-2419104-B1 | COMBINATIONS OF 5-HT4 RECEPTOR AGONISTS AND ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF COGNITIVE DISORDERS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-11-08 | — | — | EP | claimed |
| US-9402840-B2 | Crystalline form of a quinolinone-carboxamide compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-20160095849-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-04-07 | — | — | US | claimed |
| US-9126994-B2 | Crystalline form of a quinolinone-carboxamide compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-08 | — | — | US | claimed |
| US-20140256769-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | claimed |
| US-20140057939-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | THERAVANCE, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-8658671-B2 | Crystalline form of a quinolinone-carboxamide compound | THERAVANCE, INC. (US) | 2014-02-25 | — | — | US | claimed |
| US-8404711-B2 | 5-HT4 receptor agonist compounds for treatment of cognitive disorders | THERAVANCE, INC. (US) | 2013-03-26 | — | — | US | claimed |
| EP-1831211-B1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2010-06-02 | — | — | EP | claimed |
| US-7728004-B2 | crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or solvate thereof; treating disease associated with 5-HT4 receptor activity; gastrointestinal tract disorder | THERAVANCE, INC. (US) | 2010-06-01 | — | — | US | claimed |
| EP-1735304-B1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-01-07 | — | — | EP | claimed |
| US-20080287486-A1 | Prokinetic agent for bowel preparation | THERAVANCE, INC. | 2008-11-20 | — | — | US | claimed |
| US-7419989-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2008-09-02 | — | — | US | claimed |
| US-20080176895-A1 | Quinolinone-carboxamide compounds as 5-HT4, receptor agonists | ALFASIGMA S.P.A. (IT) | 2008-07-24 | — | — | US | claimed |
| US-7375114-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-05-20 | — | — | US | claimed |
| US-20060229332-A1 | crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or solvate thereof; treating disease associated with 5-HT4 receptor activity; gastrointestinal tract disorder | THERAVANCE, INC. | 2006-10-12 | — | — | US | claimed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | claimed |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2005-10-13 | — | — | US | claimed |